Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma
Cancer Genomics - Proteomics · 2024
DOI: 10.21873/cgp.20435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, 2024. Verfasst von Yohei Okuda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Kidney Neoplasms, Ureteral Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: The response to immune checkpoint inhibitors (ICIs) or enfortumab vedotin is limited in patients with upper urinary tract urothelial carcinoma (UTUC), and the development of new targeted therapy for UTUC is eagerly needed. Several biomarkers, including programmed cell death-ligand 1 (PD-L1), have already been reported as predictors of response to ICIs therapy for UTUC. Recently, several studies have shown that steroid hormone receptors, including the androgen receptor (AR), are associated with progression of urothelial carcinoma. MATERIALS AND METHODS: We prepared tissue microarrays (TMA) from paraffin blocks of UTUC specimens in 99 non-metastatic UTUC patients who underwent radical nephroureterectomy. With these TMA sections, we performed immunohistochemical staining for PD-L1 and AR and examined PD-L1 and AR expression levels in tumor cells. In addition, we analyzed the correlation between these markers and clinical prognosis in UTUC cases. RESULTS: PD-L1 was positive in 24 (24%) of the 99 samples, whereas AR was positive in 20 (20%) patients. AR-negative samples had significantly higher PD-L1 expression level than that the AR-positive samples (mean value 4.70% versus 2.55%, p=0.0324). Among AR-positive cases, patients with absence of PD-L1 expression had significantly lower cancer-specific survival (CSS) than that in PD-L1 expression-positive cases (p=0.049), although PD-L1 expression had no significant impact on CSS in AR-negative cases (p=0.920). CONCLUSION: Our findings suggest that AR is the promising target for UTUC treatment, especially in PD-L1-negative cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan; kato@uro.med.oaska-u.ac.jp.
- Department of Urology, Kindai University Faculty of Medicine, Sayama, Japan.
- Department of Pathology, Osaka General Medical Center, Osaka, Japan.
- Departments of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A.
- Urology, University of Rochester Medical Center, Rochester, NY, U.S.A.
Zitieren
APA
Okuda, Y., Kato, T., Fujita, K., Fushimi, H., Miyamoto, H., Netto, G. J., & Nonomura, N. (2024). Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma. Cancer Genomics - Proteomics. https://doi.org/10.21873/cgp.20435
Vancouver
Okuda Y, Kato T, Fujita K, Fushimi H, Miyamoto H, Netto GJ, et al. Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma. Cancer Genomics - Proteomics. 2024. doi:10.21873/cgp.20435
BibTeX
@article{Okuda2024,
author = {Okuda, Yohei and Kato, Taigo and Fujita, Kazutoshi and Fushimi, Hiroaki and Miyamoto, Hiroshi and Netto, George J and Nonomura, Norio},
title = {Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma},
journal = {Cancer Genomics - Proteomics},
year = {2024},
doi = {10.21873/cgp.20435}
}
EUVIMED